[go: up one dir, main page]

MX2017014033A - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas. - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.

Info

Publication number
MX2017014033A
MX2017014033A MX2017014033A MX2017014033A MX2017014033A MX 2017014033 A MX2017014033 A MX 2017014033A MX 2017014033 A MX2017014033 A MX 2017014033A MX 2017014033 A MX2017014033 A MX 2017014033A MX 2017014033 A MX2017014033 A MX 2017014033A
Authority
MX
Mexico
Prior art keywords
prophylaxis
derivatives
novel
treatment
compounds
Prior art date
Application number
MX2017014033A
Other languages
English (en)
Other versions
MX376761B (es
Inventor
Yun Hongying
Zheng Xiufang
Wang Jianping
Liang Chungen
Miao Kun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017014033A publication Critical patent/MX2017014033A/es
Publication of MX376761B publication Critical patent/MX376761B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), Ver fórmula (I), en la que R1, R2 y R3 son como se han descrito en el presente documento, y sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.
MX2017014033A 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas. MX376761B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (2)

Publication Number Publication Date
MX2017014033A true MX2017014033A (es) 2018-03-01
MX376761B MX376761B (es) 2025-03-07

Family

ID=55910966

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014033A MX376761B (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas.
MX2020010949A MX2020010949A (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010949A MX2020010949A (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.

Country Status (33)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR102690131B1 (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HK (1) HK1247925A1 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX376761B (es)
MY (1) MY182353A (es)
NZ (2) NZ775222A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI768467B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775222A (en) 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2019002129A (es) * 2016-08-29 2019-06-20 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
CA3034185A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
BR112020016509A2 (pt) * 2018-02-28 2020-12-15 F. Hoffmann-La Roche Ag Composto, composto para uso no tratamento ou profilaxia do câncer de fígado, composição farmacêutica ou medicamento, uso e método para o tratamento ou profilaxia do câncer de fígado
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
US20220226488A1 (en) * 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN114450280B (zh) 2019-09-20 2025-02-25 先正达农作物保护股份公司 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物
CN119604517A (zh) 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
AP2011005745A0 (en) * 2008-12-09 2011-06-30 Gilead Sciences Inc Modulators of toll-like receptors.
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
AU2012334127B2 (en) 2011-11-09 2017-05-18 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
JP6336036B2 (ja) 2013-03-29 2018-06-06 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療のための大環状デアザプリノン
PT3190113T (pt) 2014-08-15 2021-06-17 Chai Tai Tianqing Pharmaceutical Group Co Ltd Compostos pirrolopirimidina utilizados como agonistas de tlr7
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2019002129A (es) * 2016-08-29 2019-06-20 Hoffmann La Roche Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.

Also Published As

Publication number Publication date
AU2020256348B2 (en) 2022-06-16
US20160326177A1 (en) 2016-11-10
CL2017002745A1 (es) 2018-05-18
ES2753777T3 (es) 2020-04-14
TW201716410A (zh) 2017-05-16
BR112017023959B1 (pt) 2023-05-02
SI3294740T1 (sl) 2019-12-31
UA120450C2 (uk) 2019-12-10
HK1247925A1 (zh) 2018-10-05
AU2022204666A1 (en) 2022-07-21
CR20170496A (es) 2017-12-05
CN107580596A (zh) 2018-01-12
IL280769B1 (en) 2023-03-01
NZ775222A (en) 2024-09-27
CA2982704A1 (en) 2016-11-17
HUE045906T2 (hu) 2020-01-28
IL254947A0 (en) 2017-12-31
RU2017142577A (ru) 2019-06-10
PT3294740T (pt) 2019-10-29
US20170275286A1 (en) 2017-09-28
JP2018515509A (ja) 2018-06-14
SG10202108841YA (en) 2021-09-29
JP6738352B2 (ja) 2020-08-12
LT3294740T (lt) 2019-11-25
US20200109144A1 (en) 2020-04-09
US11242345B2 (en) 2022-02-08
RS59435B1 (sr) 2019-11-29
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
IL280769A (en) 2021-04-29
TWI706954B (zh) 2020-10-11
IL280769B2 (en) 2023-07-01
US10399983B2 (en) 2019-09-03
HRP20191942T1 (hr) 2020-01-10
KR102690131B1 (ko) 2024-07-31
NZ735648A (en) 2023-06-30
PH12017502009A1 (en) 2018-03-26
EP3294740A1 (en) 2018-03-21
AU2016260683A1 (en) 2017-10-12
TWI768467B (zh) 2022-06-21
CO2017009994A2 (es) 2018-02-20
US9708325B2 (en) 2017-07-18
IL254947B (en) 2021-02-28
CA2982704C (en) 2023-10-24
PL3294740T3 (pl) 2020-03-31
MY182353A (en) 2021-01-20
PE20171620A1 (es) 2017-11-02
WO2016180695A1 (en) 2016-11-17
AU2016260683B2 (en) 2020-10-29
EP3294740B1 (en) 2019-09-04
KR20180003612A (ko) 2018-01-09
RU2017142577A3 (es) 2019-10-31
MX376761B (es) 2025-03-07
AR104528A1 (es) 2017-07-26
MX2020010949A (es) 2022-06-16
BR112017023959A2 (pt) 2018-07-17
CN107580596B (zh) 2020-07-14
AU2020256348A1 (en) 2020-11-12
DK3294740T3 (da) 2019-11-04

Similar Documents

Publication Publication Date Title
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX2017014033A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
UY36702A (es) Piridinas sustituidas y métodos de uso
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo
NI201600171A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
DOP2016000326A (es) Compuestos de dihidroisoquinolinona sustituida

Legal Events

Date Code Title Description
FG Grant or registration